Search results
Results from the WOW.Com Content Network
Currently, however, inflammatory pseudotumor designates a large and heterogeneous group of soft tissue tumors that includes inflammatory myofibroblastic tumor, plasma cell granuloma, xanthomatous pseudotumor, solitary mast cell granuloma, inflammatory fibrosarcoma, [4] pseudosarcomatous myofibroblastic proliferation, myofibroblastoma ...
Medical imaging may suggest but cannot prove that a tumor is MFB. Mammography, computed tomography scans, and magnetic resonance imaging of mammary [1] [12] and extramammary [1] [13] MFB typically show well-defined and well-circumscribed tumors which in almost all cases have no calcifications; these results suggest that the tumor is not malignant but do not indicate which type it might be.
Mammary-type myofibroblastoma [14] Myofibrobastoma, also termed myofibroblastoma of soft tissues, is a mammary-type myofibroblastoma that occurs in non-mammary tissues [15] and may be as much as 10-fold more common than the mammary type. [14] Calcifying aponeurotic fibroma, also termed aponeurotic fibroma [16]
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
The drug was approved to treat acute myeloid leukemia. [199] Two other drugs, trastuzumab emtansine and brentuximab vedotin, are both in late clinical trials, and the latter has been granted accelerated approval for the treatment of refractory Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. [197]
Intranodal palisaded myofibroblastoma (IPM) is a rare primary tumour of lymph nodes, that classically presents as an inguinal mass. [ 1 ] It afflicts predominantly males of middle age.
The concept of blocking PD-1 and PD-L1 for the treatment of cancer was first published in 2001. [6] Pharmaceutical companies began attempting to develop drugs to block these molecules, and the first clinical trial was launched in 2006, evaluating nivolumab.